Down Nearly 50% From Its 52-Week High, Is CRISPR Therapeutics a Steal of a Deal?The Motley Fool • 09/05/24
Why Is CRISPR Therapeutics (CRSP) Down 7.7% Since Last Earnings Report?Zacks Investment Research • 09/04/24
Crispr Therapeutics Q2 Earnings: Casgevy Updates Underline 'Blockbuster' PotentialSeeking Alpha • 08/07/24
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/05/24
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial ResultsGlobeNewsWire • 08/05/24
Analysts Estimate CRISPR Therapeutics AG (CRSP) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 07/29/24
CRISPR Therapeutics AG (CRSP) Ascends But Remains Behind Market: Some Facts to NoteZacks Investment Research • 07/26/24